Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates-Reference-Cited by-同舟云学术

Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates

Published:2021-09-17 Issue:10 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Carattoli Alessandra¹^ORCID,Arcari Gabriele¹,Bibbolino Giulia²,Sacco Federica¹³,Tomolillo Dario¹,Di Lella Federica Maria³⁴,Trancassini Maria⁵³,Faino Luigi⁶,Venditti Mario⁵,Antonelli Guido¹³,Raponi Giammarco⁵³

Affiliation:

1. Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

2. Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Naples, Italy

3. Microbiology and Virology Unit, University Hospital Policlinico Umberto I, Rome, Italy

4. Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy

5. Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

6. Department of Environmental Biology, Sapienza University of Rome, Rome, Italy

Abstract

From January 2019 to April 2020, 32 KPC-producing, ceftazidime-avibactam (CZA)-resistant Klebsiella pneumoniae strains were isolated in a university hospital in Rome, Italy. These strains belonged to the sequence type 512 (ST512), ST101, and ST307 high-risk clones.

Funder

Sapienza Università di Roma

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00574-21

Reference60 articles.

1. Extended-Spectrum β-Lactamases: a Clinical Update

2. Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance

3. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis